Chimeric Antibodies for SARS-CoV-2 Spike Protein Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current countermeasures against SARS-COV-2 are inadequate, with over 350 million infections and a pressing need for effective monitoring and treatment tools.
Innovation Solution
Development of an antibody composition with high sequence identity to the SARS-COV-2 spike protein or its mutants, capable of binding to the receptor binding domain or N-terminal domain, which can be used for treatment, prevention, and identification of SARS-COV-2 infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional countermeasures are used against SARS-COV-2, then current treatment and monitoring methods are available, but they are inadequate with over 350 million infections
Solution Approach 1:
The patent develops chimeric antibodies with optimized amino acid sequences (at least 80% identity to SEQ ID NOs: 1-114) that specifically bind to SARS-COV-2 spike protein variants. This parameter optimization enhances neutralization effectiveness across multiple variants including Alpha, Beta, Gamma, Delta, and Omicron, directly addressing the inadequacy of conventional countermeasures
Solution Approach 2:
The invention creates composite antibody structures by combining heavy chains (SEQ ID NOs: 1-57) and light chains (SEQ ID NOs: 58-114) to form chimeric antibodies. This composite approach enables broad-spectrum neutralization activity against multiple coronavirus variants, improving reliability of countermeasures beyond what single antibodies can achieve
2Reliability
If antibody composition is designed to recognize spike protein or mutants, then binding affinity to receptor binding domain is improved, but sequence identity requirements increase complexity
Solution Approach 1:
The patent specifies precise sequence identity parameters (at least 80%, 85%, 90%, or 95% identity to reference sequences) to optimize binding affinity while maintaining manageability. This parameter-based approach allows systematic optimization of antibody-spike protein interactions without excessive complexity
Solution Approach 2:
The chimeric antibodies are designed with sequence identities that enable them to bind multiple spike protein variants (Alpha, Beta, Gamma, Delta, Omicron) simultaneously. This multi-functional design achieves broad-spectrum neutralization while using standardized sequence identity criteria that simplify rather than complicate the system
3Reliability
If antibody composition neutralizes pseudovirions effectively, then therapeutic benefit is improved, but manufacturing and characterization complexity increases
Solution Approach 1:
The patent establishes specific sequence identity thresholds (80-95% identity to reference sequences) that balance neutralization effectiveness with manufacturing feasibility. These parameter specifications enable standardized production protocols and quality control measures, making complex antibody compositions manufacturable
Solution Approach 2:
The chimeric antibodies are constructed from separate heavy chain and light chain components with defined sequences. This segmentation allows independent optimization, purification, and quality control of each chain before assembly, simplifying the manufacturing process while maintaining high neutralization effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody composition effectively neutralizes SARS-COV-2 pseudovirions and provides therapeutic and prophylactic benefits by binding to the spike protein, offering a method for treating and preventing infections, as well as identifying the virus in biological samples.
Implementation Method 1
an antibody composition that recognizes the spike protein or mutants thereof of a coronavirus
Data Source
AI summary
Compositions and methods are disclosed for treating and/or preventing coronavirus infection and related pathologies. The compositions include antibodies having certain defined heavy and light chain sequences that recognize the coronavirus spike protein or mutants thereof.